267 related articles for article (PubMed ID: 24220620)
1. Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia.
Malhotra J; Kremyanskaya M; Schorr E; Hoffman R; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):31-6. PubMed ID: 24220620
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy.
Javorniczky NR; Wehrle J; Ihorst G; Hupfer V; Aumann K; Pfeifer D; Niemöller C; Bleul S; Pantic M; Werner M; Duyster J; Finke J; Engelhardt M; von Bubnoff N; Waller CF; Pahl HL; Becker H
Leuk Res; 2020 Nov; 98():106454. PubMed ID: 32971364
[TBL] [Abstract][Full Text] [Related]
3. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
4. The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes.
Le Clech L; Sakka M; Meskar A; Kerspern H; Eveillard JR; Berthou C; Buors C; Lippert E; Guillerm G; Quintin-Roué I; Carré JL; Ianotto JC
Leuk Lymphoma; 2017 Nov; 58(11):2582-2587. PubMed ID: 28482711
[TBL] [Abstract][Full Text] [Related]
5. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.
Dentali F; Ageno W; Rumi E; Casetti I; Poli D; Scoditti U; Maffioli M; di Minno MN; Caramazza D; Pietra D; De Stefano V; Passamonti F
Thromb Res; 2014 Jul; 134(1):41-3. PubMed ID: 24787989
[TBL] [Abstract][Full Text] [Related]
6. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.
Rampal R; Mascarenhas J
Curr Opin Hematol; 2014 Mar; 21(2):65-71. PubMed ID: 24366192
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathology of myeloproliferative neoplasms.
Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
[TBL] [Abstract][Full Text] [Related]
9. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
Koopmans SM; van Marion AM; Schouten HC
Neth J Med; 2012 May; 70(4):159-67. PubMed ID: 22641623
[TBL] [Abstract][Full Text] [Related]
10. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
Santana-Davila R; Tefferi A; Holtan SG; Ketterling RP; Dewald GW; Knudson RA; Steensma DP; Chen D; Hoyer JD; Hanson CA
Leuk Res; 2008 Dec; 32(12):1927-30. PubMed ID: 18538839
[TBL] [Abstract][Full Text] [Related]
11. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
Tallarico M; Odenike O
Curr Hematol Malig Rep; 2015 Jun; 10(2):112-7. PubMed ID: 25893311
[TBL] [Abstract][Full Text] [Related]
12. Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm.
Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Kim SY; Jo DY
Blood Res; 2022 Mar; 57(1):59-68. PubMed ID: 35256550
[TBL] [Abstract][Full Text] [Related]
13. Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications.
Tremblay D; Yacoub A; Hoffman R
Hematol Oncol Clin North Am; 2021 Apr; 35(2):159-176. PubMed ID: 33641861
[TBL] [Abstract][Full Text] [Related]
14. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.
Tefferi A; Vardiman JW
Leukemia; 2008 Jan; 22(1):14-22. PubMed ID: 17882280
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
[TBL] [Abstract][Full Text] [Related]
16. Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms.
Czader M; Orazi A
Am J Clin Pathol; 2015 Aug; 144(2):188-206. PubMed ID: 26185305
[TBL] [Abstract][Full Text] [Related]
17. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
18. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.
Abdulkarim K; Ridell B; Johansson P; Kutti J; Safai-Kutti S; Andréasson B
Eur J Haematol; 2011 Feb; 86(2):148-55. PubMed ID: 21059102
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms.
Khan M; Siddiqi R; Gangat N
Leuk Res; 2017 Dec; 63():78-84. PubMed ID: 29121538
[TBL] [Abstract][Full Text] [Related]
20. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
Tefferi A
Mayo Clin Proc; 1998 Dec; 73(12):1177-84. PubMed ID: 9868417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
